Personal tools

Coexpression cluster:C318

From FANTOM5_SSTAR

Revision as of 17:38, 18 May 2012 by Autoedit (talk | contribs)
Jump to: navigation, search


Full id: C318_hepatoma_Intestinal_bile_small_colon_Prostate_endometrial



Phase1 CAGE Peaks

Hg19::chr10:5048261..5048285,-p@chr10:5048261..5048285
-
Hg19::chr10:5135981..5136010,+p6@AKR1C3
Hg19::chr11:111154870..111154887,+p2@C11orf53
Hg19::chr11:111154907..111154928,+p1@C11orf53
Hg19::chr11:111154934..111154946,+p3@C11orf53
Hg19::chr11:111154964..111154975,+p4@C11orf53
Hg19::chr11:111175739..111175773,-p6@C11orf92
Hg19::chr11:111175775..111175789,-p7@C11orf92
Hg19::chr11:111176063..111176079,-p8@C11orf92
Hg19::chr11:111176084..111176102,-p9@C11orf92
Hg19::chr11:111176104..111176114,-p11@C11orf92
Hg19::chr11:69715346..69715355,-p@chr11:69715346..69715355
-
Hg19::chr11:69715376..69715382,-p@chr11:69715376..69715382
-
Hg19::chr11:69715408..69715418,-p@chr11:69715408..69715418
-
Hg19::chr14:23445970..23445991,-p6@AJUBA
Hg19::chr14:96734892..96734925,-p1@ENST00000553638
Hg19::chr16:57640858..57640869,-p@chr16:57640858..57640869
-
Hg19::chr19:41509967..41509988,+p3@CYP2B6
Hg19::chr19:41510133..41510160,+p@chr19:41510133..41510160
+
Hg19::chr1:197928283..197928310,+p@chr1:197928283..197928310
+
Hg19::chr3:30226342..30226387,-p@chr3:30226342..30226387
-
Hg19::chr4:72468240..72468271,+p@chr4:72468240..72468271
+
Hg19::chr5:1201465..1201468,+p11@SLC6A19
Hg19::chr5:1201536..1201542,+p4@SLC6A19
Hg19::chr5:1202241..1202252,-p@chr5:1202241..1202252
-
Hg19::chr5:68339691..68339711,-p1@ENST00000479830
Hg19::chr6:132935900..132935911,-p@chr6:132935900..132935911
-
Hg19::chr7:107875370..107875381,-p@chr7:107875370..107875381
-
Hg19::chr8:100519343..100519351,+p@chr8:100519343..100519351
+
Hg19::chr8:100519383..100519390,+p@chr8:100519383..100519390
+
Hg19::chr8:17767866..17767892,-p4@FGL1
Hg19::chr9:22113541..22113546,+p3@CDKN2B-AS
Hg19::chr9:22113608..22113615,+p17@CDKN2B-AS
Hg19::chr9:38437671..38437689,+p@chr9:38437671..38437689
+
Hg19::chr9:38437690..38437712,+p@chr9:38437690..38437712
+
Hg19::chr9:38437716..38437729,+p@chr9:38437716..38437729
+
Hg19::chr9:38437744..38437747,+p@chr9:38437744..38437747
+


Enriched pathways on this co-expression cluster<b>Summary:</b><br>Canonical pathway gene sets were compiled from Reactome, Wikipathways and KEGG. For the major signaling pathways, the transcriptionally-regulated genes (downstream targets) were obtained from Netpath. Combined, the canonical pathways and downstream targets totaled 489 human gene sets. The corresponding M. musculus gene sets were inferred by homology using the HomoloGene database. Enrichment for each of the canonical 489 pathways and gene sets included in the co-expression cluster was assessed by the hypergeometric probability. The resulting P values were also then adjusted by the Benjamini-Hochberg method for multiple comparisons.<br><b>Analyst: </b>Emmanuel Dimont<br><br>link to source dataset<br>data


No results for this coexpression

Enriched Gene Ontology terms on this co-expression cluster<b>Summary:</b> Results for GOStat analysis on co-expressed clusters. Each cluster with promoters mapping to at least two different genes was analysed with GOStat (PMID: 14962934) with default parameter. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br>data


GO IDGO nameFDR corrected p-value
GO:0047017prostaglandin-F synthase activity0.00874172177855952
GO:00470263-alpha-hydroxysteroid dehydrogenase (A-specific) activity0.00874172177855952
GO:0047045testosterone 17-beta-dehydrogenase (NADP+) activity0.00874172177855952
GO:0047115trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity0.00874172177855952
GO:0050327testosterone 17-beta-dehydrogenase activity0.0093240915001036
GO:0005577fibrinogen complex0.0165019362595048
GO:0004033aldo-keto reductase activity0.0165019362595048
GO:0015804neutral amino acid transport0.0165019362595048
GO:0016628oxidoreductase activity, acting on the CH-CH group of donors, NAD or NADP as acceptor0.0165019362595048
GO:0006693prostaglandin metabolic process0.0165019362595048
GO:0006692prostanoid metabolic process0.0165019362595048
GO:0015175neutral amino acid transmembrane transporter activity0.0165019362595048
GO:0006118electron transport0.0201970832734816
GO:0050381unspecific monooxygenase activity0.0216241942435844
GO:0016229steroid dehydrogenase activity0.024833518960349
GO:0006091generation of precursor metabolites and energy0.0272454932255383
GO:0016712oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen0.0306091097628793
GO:0006690icosanoid metabolic process0.0306091097628793
GO:0005328neurotransmitter:sodium symporter activity0.0306091097628793
GO:0005326neurotransmitter transporter activity0.0308192896656132
GO:0015171amino acid transmembrane transporter activity0.034874355006795
GO:0006865amino acid transport0.0369765176591999
GO:0006836neurotransmitter transport0.037764746818911
GO:0016627oxidoreductase activity, acting on the CH-CH group of donors0.037764746818911
GO:0015837amine transport0.037764746818911
GO:0015370solute:sodium symporter activity0.037764746818911
GO:0046943carboxylic acid transmembrane transporter activity0.037764746818911
GO:0046942carboxylic acid transport0.037764746818911
GO:0015849organic acid transport0.037764746818911
GO:0005342organic acid transmembrane transporter activity0.037764746818911
GO:0016491oxidoreductase activity0.037764746818911
GO:0015294solute:cation symporter activity0.0413201004265023



Enriched sample ontology terms on this co-expression cluster<b>Summary:</b>To summarize promoter activities (expression profile of a TSS region) across ~1000 samples, we performed enrichment analysis based on FANTOM5 Sample Ontology (FF ontology). The question here is “in which type of samples the promoter is more active”. To answer this question, we compared expressions (TPMs) in the samples associated with a sample ontology term and the rest of the samples by using the Mann-Whitney rank sum test. To summarize ontologies enriched in this co-expression cluster, we ran the same analysis on an averaged expression profile of all promoters that make up. <b>Analyst:</b> Hideya Kawaji <br><br>links to source dataset<br><br>cell_data<br>uberon_data<br>disease_data<br>


Cell Type
Ontology termp-valuen

Uber Anatomy
Ontology termp-valuen

Disease
Ontology termp-valuen


Overrepresented TFBS (DNA) motifs on this co-expression cluster<b>Summary:</b>The values shown are the p-values for overrepresentation of the motif in this coexpression cluster. So a small p-value means a strong overrepresentation. <b>Analyst:</b> Michiel de Hoon <br><br>link to source data <br> Novel motifs <br>data <br><br> Jaspar motifs <br>data


Novel motifs



JASPAR motifs

Motifs-log10(p-value)

{{{tfbs_overrepresentation_jaspar}}}



ENCODE TF ChIP-seq peak enrichment analysis<b>Summary:</b> For each TF and each co-expression cluster, the number of promoters with ENCODE TF ChIP signal was compared with the rest of promoters from the robust set using Fisher's exact test. Clusters with significant ChIP enrichment (q <= 0.05) after Benjamini-Hochberg correction were retained. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br><br>data


No analysis results for this cluster

Relative expression of the co-expression cluster<b>Summary:</b>Co-expression clusters are compared against FANTOM5 samples to obtain relative expression. <br><b>Analyst:</b>NA<br><br>link to data source<br> data


This analysis result is provided for C0 - C305 clusters.